Medisys Technologies, Inc. Supports the New Federal Needlestick Safety Prevention Act Passed by the House

Medisys Technologies, Inc. Supports the New Federal Needlestick Safety Prevention Act Passed by the House

Business Wire - October 5, 2000

BATON ROUGE, La. & FAR HILLS, N.J.--(BW HealthWire)--Oct. 5, 2000--Medisys Technologies, Inc. (OTCBB: SCEP) enthusiastically supports the HR 5178 Needlestick Safety Prevention Act introduced congress by Rep. Cass Ballenger (R-NC) and Rep. Mayor Owend (D-NY) to amend the Bloodborne Pathogen Standard administered by the Occupational Safety and Health Administration (OSHA) to require the use of safer devices to protect from sharp injuries. The House passed the bill on Tuesday 10/3/00.

The new bill would also require employers to maintain a sharps injury log to contain, the type and brand of device involved in the incident; the department or work area where the exposure incident occurred; and an explanation of how the incident occurred. The information would be recorded and maintained in a way that would protect the confidentiality of the injured employees. The log would be an important source of data for researchers to determine the relative effectiveness and safety of devices now on the market and those that may be developed in the future.

"We applaud the by-partisan efforts of the House to implement the use of leading edge technology to safeguard our nation's health care providers," says Edward P. Sutherland, CEO of Medisys Technologies. "Medisys is committed to providing technologically advanced medical devices that meet and exceed national safety standards to provide superior patient care and ultimately, safety for the healthcare providers."

Medisys Technologies Inc. has successfully developed and had subsequently been granted FDA 510K clearance to market its patented CoverTip(TM) safety needle device which the company believes provides superior protection against accidental needlesticks.

CoverTip is used just as any standard syringe with insertion of the needle into the patient's skin and depression of the syringe plunger to inject the medicine. A micro-thin sheathe covers the tip of the needle after injection of the medical fluid. When the syringe plunger is pressed and the medicinal fluid injected, the plunger contacts an actuator that engages the sleeve that locks over and blunts the tip of the needle, providing protection prior to the removal of the needle from the patient's skin.

About Medisys Technologies

Medisys Technologies, Inc. is a diversified medical company that develops, manufactures and markets patented products for improving safety and patient care. Spurred by recent Federal Regulations and State Safety Legislation Medisys is currently concentrating on commercializing its portfolio of patented needle safety technology, with unique features and competitive advantages over other safety devices.

In addition to the CoverTip hypodermic syringe, the Medisys portfolio of patented safety devices includes: BXDraw(TM), a fine needle biopsy/aspiration safety syringe; SofDraw(TM), a blood and fluid collection safety syringe; and MultiDraw(TM), a needleless multiple vacuum vial blood collection safety device. The Company has a total of 19 patent applications for new safety designs in blood collection, capillary blood testing, and tissue excision cutting needles and has granted 510K clearance by the FDA to market its products.

For more information about Medisys Technology and its proprietary suite of needle safety technologies, please contact Shayne Payne, Juan Dominguez or Dian Griesel, Ph.D. at the Investor Relations Group: 212 736 2650 or visit us on the web at www.medisystech.com

Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: Except for historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including but not limited to economic, competitive, governmental and technological factors affecting the Company's operations, markets, products and prices and other factors discussed in the Company's various filings with the Securities and Exchange Commission.

CONTACT: The Investor Relations Group, New York Shayne Payne / Dian Griesel, Ph.D. 212/736-2650
001005
BW001002

Copyright © 2000 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .